Quick Take
Freeline Therapeutics Holdings plc (FRLN) has filed to raise $100 million in an IPO of its ADSs representing underlying ordinary shares, according to an F-1 registration statement.
The company is a gene therapy biopharma developing treatments for hemophilia B and other serious systemic diseases.
FRLN has produced enviable early Phase 1 / 2 trials results for its lead candidate for the treatment of Hemophilia B.
I look forward to learning more about the IPO in future filings.
Company & Technology
Hertfordshire, UK-based Freeline was founded to develop its AAV-based gene